**Review Article**

**Dried Blood Spots for Global Health Diagnostics and Surveillance: Opportunities and Challenges**

Mark D. Lim*  
Global Health Division, Bill & Melinda Gates Foundation, Seattle, Washington

Abstract. There is increasing interest in using dried blood spot (DBS) cards to extend the reach of global health and disease surveillance programs to hard-to-reach populations. Conceptually, DBS offers a cost-effective solution for multiple use cases by simplifying logistics for collecting, preserving, and transporting blood specimens in settings with minimal infrastructure. This review describes methods to determine both the reliability of DBS-based bioanalysis for a defined use case and the optimal conditions that minimize pre-analytical sources of data variability. Examples by the newborn screening, drug development, and global health communities are provided in this review of published literature. Sources of variability are linked in most cases, emphasizing the importance of field-to-laboratory standard operating procedures that are evidence based and consider both stability and efficiency of recovery for a specified analyte in defining the type of DBS card, accessories, handling procedures, and storage conditions. Also included in this review are reports where DBS was determined to not be feasible because of technology limitations or physiological properties of a targeted analyte.

**INTRODUCTION**

Most diagnostics and surveillance programs rely on measurements from an individual’s blood specimen to guide a clinical or public health decision. To minimize pre-analytical sources of data variability, processes for venipuncture collection are standardized through devices such as analyte-specific blood collection tubes and evidence-based best practices, guidelines, and protocols. Global health settings often lack infrastructure for quality-assured venipuncture, sparking significant interest in the use of dried blood spot (DBS) cards as a universal solution. The intent of this review is to underscore the need to assess the reliability of DBS-based bioanalysis in context to a specific biomarker and envisioned field-to-laboratory workflow, before applying this technology into a remote health or surveillance program.

Compared with venipuncture, the value proposition of DBS is simplified logistics for remote sampling through:

- Reduced workforce requirements
- Smaller volumes of blood and components (plasma and serum)
- Direct heelprick/fingerprick-to-DBS or indirect capillary-to-DBS deposition of blood
- Collection of nonblood biofluids such as saliva
- Simplified transport, shipment, and disposal
- Simplified biobanking for retrospective analysis

Commercially available DBS cards are not designed for the minimally resourced environments typical of remote health settings and instead are primarily used in newborn screening and preclinical drug development by highly proficient personnel within controlled clinical and laboratory environments. For instance, most DBS are susceptible to contamination by the user, patient, environment, insects, equipment, or contact with other cards. Health-care workers also have a risk of exposure to potentially infectious agents until blood is dried and contained in secure packaging. Most of these risks can be mitigated through standard operating procedures and accessories, but the impact of these variables on data quality needs to be assessed through careful studies simulating the pre-analytical workflow, starting with specimen acquisition to DBS preparation for analysis. Readers are advised to review the comprehensive review of mass spectrometry (MS) methods and the collection of reports compiled by Li and Lee discussing various use cases, techniques, and technologies for DBS-based bioanalysis.

Two primary global health applications envision that the use of DBS can extend either health-care services or research and surveillance studies into harder-to-reach populations. The clinical scenario aims to measure health-related diagnostic data to stratify at-risk individuals for additional confirmatory testing or to guide individual- or population-level treatment decisions. The other scenario aims to extend epidemiological surveillance that monitors population-level transmission of infection or tracks emerging or recrudescent disease. Both scenarios rely on tools that provide high-sensitivity analysis of individual samples to minimize the risk of missed positive cases, particularly in geographies where loss to follow-up remains a significant challenge. In other words, for both scenarios, false-negative test results typically have higher consequences for these programs than false-positive test results if there is an opportunity to further confirm the clinical or epidemiological status of test-positive individuals or populations.

The weakest link for sensitivity within a bioanalytical workflow is the quality of the specimen. The concept of DBS is appealing; however, these broad remote-sampling aspirations should consider the extensive literature evaluating the reliability of DBS for high-sensitivity analysis of specific biomarkers. In most instances, quantitative studies have demonstrated the feasibility of DBS if standardized collection and laboratory protocols are followed. However, there are examples where DBS fails to provide reliable results and this review includes a sample of these reports.
BACKGROUND

The concept of depositing fingerprick-derived blood on laboratory filter paper, the precursor of DBS, was first described in the 1860s for glucose measurements\textsuperscript{15} and in the 1960s for screening metabolic disorders in newborns using heelprick-derived blood.\textsuperscript{19} One of the popular DBS formats is the Whatman 903 card, which is composed of cotton-based filter paper within a rigid cardboard frame for handling and labeling. The paper is ink-printed with five half-inch circles that direct the user to the location for depositing a specimen.

Blood-deposited cards are typically dried in an open environment by suspension in ambient air or under forced circulation in a laboratory or hospital.\textsuperscript{20} Dried blood spots are often stored for transport in a sealed bag with desiccant and archived under refrigerated or frozen conditions.\textsuperscript{15,16} Portions of the dried spot are “punched” out with a regular hole puncher or scissors, specialized DBS punchers and protocols are both available to reduce risk of contamination by card-to-card carryover.\textsuperscript{21–24} The whole spot can also be used if there are no plans to re-analyze or archive the specimen.

The panel of diseases screened by newborn programs has significantly expanded since Guthrie’s first application of DBS\textsuperscript{25} with interest to use this technology in global health strategies.\textsuperscript{4,10,11,26–31} Given the implications of test results on treatment decisions or public health resources, published protocols and guidelines aiming to minimize the risk of pre-analytical variability are regularly evaluated and updated.\textsuperscript{5,16,20,32} Some assessments have found that a diagnostic cutoff determining one decision over another may be dependent on the type of platform used to analyze a DBS-derived specimen, such as those using human immunodeficiency virus (HIV) viral load measurements to determine treatment effectiveness\textsuperscript{27,35–40} or polymerase chain reaction (PCR) analysis of malarial DNA.\textsuperscript{41} These findings stress the importance of assessing and mitigating sources of data variability within a complete field-to-laboratory pre-analytical workflow, starting with the type of DBS and the platform used for downstream analysis of a specific biomarker (Figure 1).

The drug development sector is another early adopter, envisioning that DBS provides a simplified and cost-effective approach for measuring drug metabolites and toxicity biomarkers in preclinical animal studies.\textsuperscript{42–44} This community published most of the quantitative evaluations in an effort to support claims on the equivalency of DBS-based data to data from venipuncture.\textsuperscript{18,45–47} Recent efforts to evaluate the feasibility of DBS for remote clinical trials have also been met with successes and challenges.\textsuperscript{30,48–56} One common conclusion from the newborn screening and drug development communities is the importance of storing DBS cards in refrigerated and desiccated conditions as soon as the specimen is dried to reduce data variability. The impact of these mitigation measures is dependent on the individual stability and physiological profiles of a specific analyte with frozen biobanking conditions still failing to provide sufficient stabilization over extended periods of time for many analytes. Some of the literature reviews summarizing the feasibility of DBS in global health applications include hepatitis B and C,\textsuperscript{8,29,57–61} HIV,\textsuperscript{8,27,62–66} and malaria.\textsuperscript{30}

Evaluations of discordant DBS results identified sources of variability that include

- Interindividual differences, with a particular emphasis on hematocrit (Hct)

**TABLE 1**

| VARIABLE | DESCRIPTION |
|----------|-------------|
| Hct      | Hematocrit  |

**Hematocrit.** The predominant source of interindividual variability studied in the DBS literature is Hct, a measurement representing the percentage of red blood cells in a known
volume of blood. These clinical measurements are used to determine if a patient has anemia and can vary by age, gender, health, living environment, and nutritional status. From a chemical and materials perspective, a blood sample with an elevated Hct would have increased viscosity because of the higher percentage of red blood cells. As described in several reports, a viscous blood drop would have a less homogenous distribution of analytes, the impact of this variability on test results can be significant. In addition, per-punch volumes of whole blood, red blood cells, and serum were differentially impacted by Hct level, potentially affecting reliability of test results if targeted analytes naturally partition between these blood components.

In addition to physical dynamics, several studies evaluated the impact of Hct on the measurement of individual markers. For instance, most newborn screening panels include congenital hypothyroidism, a condition with no visible symptoms and without immediate treatment that could result in mental retardation. The risk of a newborn developing this condition is determined by quantitation of thyroid-stimulating hormone (TSH, thyrotropin), a peptide of approximately 200 amino acids. Butler et al. reported that an increase in Hct resulted in an artificial and clinically significant decrease in TSH concentration, using DBS samples collected as part of a newborn screening program. Although the opposite effect (decreased Hct, increased TSH) was also observed, false-negative test results caused by an Hct-influenced decrease of TSH have greater health implications, particularly if this measurement is used for a primary screen.

Unfortunately, there is no direct method to determine Hct directly from a DBS sample. As mentioned earlier, the diameter of the total blood spot has been shown to have little change over a range of Hct and an endogenous or exogenous marker has yet to be validated. One suggestion is to control the total volume of blood deposited on a DBS using a volumetric capillary or fixed-volume accessory, or even a volumetric absorptive microsampling. Another possible mitigation is to ensure that the complete dried spot, including colorless plasma, is used for analysis rather than an aliquoted punch. If the whole DBS circle is not used, location of punch relative to the whole spot should remain consistent along with annotation of an individual’s Hct.

**Analyte abundance in venous versus capillary blood.** There are several reports describing a difference in the natural abundance of biomarkers between capillary and venous blood, some of which are described in Table 2. For low-abundant analytes, the impact of this variability on test results is likely to be amplified, given that smaller volumes of blood collected in DBS increase the probability of false-negative detection. Unlike venous blood draw, there is also a higher risk for inconsistent volumes with static fingerstick- or heelprick-drawn blood; “milking” the skin puncture to increase volume through direct pressure also increases risk for hemoconcentration.

### Table 1

Examples of commercially available dried blood spot cards and accessories (no endorsements should be implied by their listing in the table)

| Brand name | Use case | Manufacturer |
|------------|----------|--------------|
| GE/Whatman FTA DMPK-A (Refs. 89,149) | Cellulose-based paper; DNA stabilization with smaller blood volumes (10–20 μL) compared with FTA/DMPK-B; Impregnated with radical inhibitors [sodium dodecyl sulfate, tris (hydroxymethyl)aminomethane] | GE Healthcare |
| GE/Whatman FTA DMPK-B (Refs. 89,149) | Cellulose-based paper; Similar to FTA DMPK-A, but blood spot area is 20% larger; Impregnated with chaotropic agents (guanidium thiocyanate) | GE Healthcare |
| GE/Whatman FTA DMPK-C (Refs. 89,149) | Cotton-based paper; No impregnated stabilization chemicals, claimed to be suitable for protein-based analysis | GE Healthcare |
| GE/Whatman 903 sample collection cards (Refs. 89,149) | Cotton-based paper; Manufactured in slightly acidic environment, compared with FTA DMPK-C | GE Healthcare |
| PerkinElmer/Ahlstrom 226 | Cotton-based, no impregnated stabilization chemicals | PerkinElmer |
| HemaSpot-HF blood collection device | Collection, storage, and aliquots of finger-stick blood | Spot on Sciences |
| HemaSpot-SE blood separation device | Separation of serum/plasma from finger-stick blood | Spot on Sciences |
| Advance Dx | Separation of serum from finger-stick blood | Advance Dx |
| Mitra microsampler | Fixed-volume blood collection (volumetric absorptive microsampling) | Neoteryx |

DMPK = drug metabolism and pharmacokinetics; FTA = Flinders Technology Associates.
Different hemoglobin concentrations were measured when fingerprick blood was extracted from either the left or right hand of the same individual. Bond and Richards-Kortum also reported higher degrees of variability in hemoglobin, white blood cell, and platelet count measurements from fingerprick-derived blood compared with venous-derived blood. In that study, collecting larger volumes of blood did not reduce the difference in total variability between capillary- and venous-derived blood (i.e., increased fingerprick volumes did not align the magnitude of variability with venous-derived blood). The authors also reported different degrees of drop-to-drop variability between patients, sharing that these results indicate interindividual physiological differences in the abundance of these analytes between the two circulatory pathways. Adding to the complexity, Hct levels were reportedly higher in capillary blood compared with venous blood in neonatal and young infants.

As demonstrated by these examples, partitioning between venous and capillary circulation is likely analyte specific and cannot be simply rationalized by smaller diameters of peripheral capillaries or mitigated by larger volumes of collected blood. Higher concentrations of some analytes in capillary blood can be attributed to hemoconcentration effects or, alternatively, lower concentrations may be due to the presence of extracellular fluid. This physiological basis for biomarker partitioning needs to be considered in guiding the clinical relevance of bioanalytical data, particularly if reported clinical correlations are based on a different source or component of blood. Assessments of analytical and clinical equivalence for any biomarker measured by capillary- and venous-derived samples should be conducted before implementing DBS within a research study or clinical workflow.

**Type of DBS.** As shown in Table 1, different DBS formats are commercially available with some claiming improved extraction efficiency or stability for specific classes of analytes. The appropriate selection of the card should be based on the analyte properties and its stabilization requirements, extraction efficiency, and method of analysis. Basic DBS formats include the paper-based Whatman 903 and Ahlstrom 226 cards, and specialized cards include the Flinders Technology Associates (FTA) Drug Metabolism and Pharmacokinetics (DMPK) cards that are impregnated with cell lysis and analyte-stabilizing materials. Flinders Technology Associates DMPK-A cards contain sodium dodecyl sulfate and tris-(hydroxymethyl)aminomethane, and FTA DMPK-B cards contain guanidium thiocyanate. Some of these chemicals have been reported to leach from DBS during sample preparation and potentially interfere with some analytical platforms through a “matrix effect,” a risk that has been evaluated extensively by the drug development community.

Analyte- and DBS-specific data variability was found between different FTA DMPK cards used for the measurement of small-molecule drugs in whole blood by liquid chromatography/MS. In addition to the matrix effect caused by impregnated chemicals, the type of paper can also influence spreading dynamics of blood across the DBS, as mentioned earlier. Distribution of antibodies across a DBS spot was found to be heterogenous and not predictable with authors suggesting that greater than 15% variability between different punches of the same spot. The impact of Hct and concentration on the recovery of small drug analytes were also dependent on the type of DBS.

Of relevance to global health applications, the variability of HIV viral load measurements was evaluated in three different types of DBS and across different RNA analysis platforms. These studies observed variable genotyping efficiencies and drug susceptibility test results from samples derived from different DBS cards; some of the authors suggest that storage conditions might mitigate paper-dependent bias. Dried blood spot–based samples were also found to result in test results that overestimate HIV incidence when compared with test results from plasma samples.

The recovery and stability of malaria-related histidine-rich protein 2 (HRP2) and mRNA were also reported to be dependent on the type of DBS. In a report by Miguel et al., none of the three commercially available reagents were able to reliably extract DNA associated with *Plasmodium falciparum* or *Plasmodium vivax* infection from blood stored on cotton-based filter paper, although others have shown a dependence on the type of DBS. The use of cards designed to preserve nucleic acids was found to provide sufficient stability for detecting single-species malaria infection but failed to diagnose individuals with mixed *P. vivax* and *P. falciparum* infections. Addressing these limitations, a method for the simultaneous extraction of nucleic acids indicating *P. vivax* and *P. falciparum* infections was developed and field-evaluated with slight differences in analytical performance reported between two types of DBS cards. Different sample
preparation methods resulted in discordant results when using PCR to detect malaria parasites, particularly if only a single aliquot/punch was used.\textsuperscript{41} These reports reinforce the need to carefully select the type of DBS card with criteria based on the properties of a specific biomarker, method for analysis, and physiochemical interactions with the card materials, in context of optimized stabilization and sample preparation.

**STORAGE CONDITIONS**

The impact of post-collection storage conditions on data quality has been extensively evaluated by multiple communities, focused on the type of card, time, temperature, humidity, and storage methods.\textsuperscript{94,106–108} These conditions include storage in the field, conditions during transport, storage before sample preparation, and longer term biobanking. The effects of these parameters are often dependent on the properties of the analyte and DBS, with a general recommendation that many of these impacts can be mitigated by storing dried cards in desiccated and frozen conditions as soon as possible.\textsuperscript{109–112}

As mentioned earlier, biobanking in frozen conditions can fail to stabilize some analytes over extended period. For example, standard protocol for HIV viral load measurements calls for the immediate storage of DBS to less than –20°C or no longer than 14 days at ambient temperature. Even if stored at –20°C, DBS cards are only reliable if these measurements are made within 2 years.\textsuperscript{10} Similar recommendations are also described for storing DBS used in newborn screening and other clinical tests.\textsuperscript{32,111,113,114}

Temperature and humidity conditions directly affect the ability to detect specific amino acids and metabolites routinely measured for newborn screening.\textsuperscript{115,116} Gene transcriptionomics analysis of newborn DBS was more consistent if samples were stored at temperatures less than –20°C immediately after specimen acquisition,\textsuperscript{111} with time and temperature imparting various degrees of degradation for specific mRNA profiling targets and housekeeping genes.\textsuperscript{112} Lower temperatures is not the solution for all analytes; three polysaturated fatty acids used to screen newborns for neural development and visual function were found to have significant degradation after 10 days of storage at –28°C, with a high degree of intra-individual variability, when measured from umbilical blood dried on Ahlstrom 226 cards.\textsuperscript{117–119}

For function-based bioanalysis, DBS storage temperatures greater than 4°C reduced the activity of all five enzymes measured to diagnose newborns at risk of lysosomal storage disorders, with the degree of variability dependent on the properties of a specific enzyme.\textsuperscript{120–123} Quantitative measurements of glucose-6-phosphate dehydrogenase (G6PD) are used by both malaria and newborn screening programs to identify individuals deficient of this essential enzyme. Two studies showed that temperature and humidity impacted quantitative measurements of G6PD activity, a source of variability that can be mitigated if DBS was stored under desiccated and refrigerated conditions.\textsuperscript{124,125}

There is emerging literature describing the pre-analytical impact of DBS storage conditions on bioanalytical test results for other diseases of global health interest such as hepatitis B and C\textsuperscript{20,68–61,126–128} and dengue.\textsuperscript{131,132} DNA measurements of \textit{P. falciparum} were affected by type of DBS, drying time, and humidity, with an overall inferior sensitivity compared with frozen whole blood.\textsuperscript{31,133–137} Incomplete drying, storage temperature, and humidity affected measurements of malaria gametocyte mRNA more significantly on samples derived from FTA DBS compared with Whatman 903 cards.\textsuperscript{100,138}

Type of DBS and storage temperature and humidity affected stability and recovery of antibodies for malarial serological surveys.\textsuperscript{139} For HRP2 measurements on Whatman 903 cards, storage at temperatures less than –20°C significantly reduced the variability of test results from archived samples.\textsuperscript{99}

For HIV drug resistance testing, HIV-1 nucleic acids were stable in DBS if stored in desiccated conditions at temperatures less than 4°C and were not recoverable if stored at 37°C under high humidity.\textsuperscript{96,140–144} Another report found that the rate of nucleic acid degradation because of storage conditions was dependent on a patient’s total viral load and preservation as dried blood or plasma.\textsuperscript{143,145} Similar to the malaria studies, drying time and handling of the specimen before biobanking affected the stability of HIV-1 RNA.\textsuperscript{146,147}

Storage environment is not just one variable and includes temperature, humidity, and time within field, transport, and laboratory settings, all in context to the stability of a specific analyte. In many instances, the type of DBS was an important consideration. Storage procedures and conditions optimizing the stability of one biomarker are likely not optimal for a different analyte. This consideration is important for those developing multiplexed detection of a panel of analytes as trade-offs in analytical performance are likely and should be evaluated in the construction of a rigorous standard operating procedure.

**DISCUSSION**

Dried blood spot offers several logistical advantages for remote health and surveillance programs, particularly for screening and surveying hard-to-reach populations. For many of these tests, a highly sensitive biomarker analysis is important for reducing the risk of missed positive cases. Analytical sensitivity not only includes the performance of a downstream platform but also the pre-analytical workflow that starts with the collection of a specimen from an individual. Quality assurance should not be the compromise of simplified logistics if incorrect test results have significant health implications or result in unnecessary expenditure of research and programmatic resources.

Although this review focused on evaluations of validated biomarkers, there is also significant interest in the use of DBS for biomarker discovery. Given current challenges of biomarker validation,\textsuperscript{80,148} DBS introduces interlinked sources of data variability that should be considered in any experimental design and statistical plan. As described in this review, significant effort is required to determine optimal conditions for specific analytes making broad standard operating procedures in the absence of an identified analyte overly simplistic. Field-collected DBS should be used sparingly in biomarker research or, at-minimum, in parallel with quality-assured venipuncture.

Several opportunities for improving the technology behind DBS should consider trade-offs with roll-to-roll DBS manufacturing processes,\textsuperscript{149} lower per-card cost, and simplified implementation logistics. In addition to direct measurements of Hct from DBS, there still lacks methods to determine the total volume of blood deposited on a card in the
absence of a volumetric accessory. Simple field-appropriate technologies are also needed to control specimen drying and maintain desiccation of a blood spot on various types of DBS until storage in controlled conditions. Technologies that prevent contamination from other DBS cards, instrumentation, or environment would also be beneficial for the community.

Broad lessons learned include the importance of evaluating the physiological, chemical, and physical properties of each analyte in context to a conceptual pre-analytical workflow that includes DBS type, collection methods, and storage conditions. The newborn screening and drug development communities, in addition to an emerging community of global health researchers, continue to build on literature evaluating the reliability of DBS. These reports provide a foundation of methods for validating of DBS-based bioanalysis and for defining standardized procedures that ensure quality and reproducible data.

Received November 15, 2017. Accepted for publication May 2, 2018.

Author’s address: Mark D. Lim, Bill & Melinda Gates Foundation, Seattle, WA, E-mail: markdlim@gmail.com.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

REFERENCES

1. Clinical and Laboratory Standards Institute, 2017. GP41: Collection of Diagnostic Venous Blood Specimens. Wayne, PA: Clinical and Laboratory Standards Institute.

2. Lim MD, Dickherber A, Compton CC, 2011. Before you analyze a human specimen, think quality, variability, and bias. Anal Chem 83: 8–13.

3. Fonjungo PN, Alemnji GA, Kebede Y, Opio A, Mwangi C, Spira TJ, Beard RS, Nkengasong JN, 2017. Combating global infectious diseases: a network effect of specimen referral systems. Clin Infect Dis 64: 796–803.

4. Smit PW, Elliott I, Peeling RW, Mabey D, Newton PN, 2014. An overview of the clinical use of filter paper in the diagnosis of tropical diseases. Am J Trop Med Hyg 90: 195–210.

5. Benyshek DC, 2010. Use of dried blood spots: an ideal tool for medical anthropology “in the field”. J Diabetes Sci Technol 4: 255–257.

6. Stove CP, Ingels A-SME, De Kesel PMM, Lambert WE, 2012. Dried blood spots in toxicology: from the cradle to the grave? Crit Rev Toxicol 42: 230–243.

7. Martial LC, Aarnoutse RE, Schreuder MF, Henriet SS, Brüggemann RJM, Joore MA, 2016. Cost evaluation of dried blood spots for monitoring HIV viral load and for early infant diagnosis of HIV infection at the primary care level: experiences and challenges in Malawi. Bull World Health Organ 94: 669–704.

8. Smit PW et al., 2014. Systematic review of the use of dried blood spots for monitoring HIV viral load and for early infant diagnosis. PLoS One 9: e68461.

9. Govender K, Parboosing R, Siyaca N, Moodley P, 2016. Dried blood spot specimen quality and validation of a new pre-analytical processing method for qualitative HIV-1 PCR, KwaZulu-Natal, South Africa. Afr J Lab Med 5: 349.

10. Gakhir A, Holodniy M, 2014. Use of dried blood spot samples in HCV-, HBV-, and influenza-related epidemiological studies. Li W, Lee MS, eds. Dried Blood Spots. Hoboken, NJ: John Wiley & Sons, Inc., 95–113.

11. Färnert A, Arez AP, Correia AT, Björkman A, Snounou G, do Rosário V, 1999. Sampling and storage of blood and the detection of malaria parasites by polymerase chain reaction. Trans R Soc Trop Med Hyg 93: 50–53.
32. Clinical and Laboratory Standards Institute. 2013. Blood Collection on Filter Paper for Newborn Screening Programs; Approved Standard—Sixth Edition, NBS01A6E. 6th edition. Wayne, PA: Clinical and Laboratory Standards Institute.

33. George RS, Moat SJ. 2016. Effect of dried blood spot quality on newborn screening analyte concentrations and recommendations for minimum acceptance criteria for sample analysis. Clin Chem 62: 466–475.

34. World Health Organization. 2010. 7, Capillary Sampling. Guidelines on Drawing Blood: Best Practices in Phlebotomy. Geneva, Switzerland: WHO. Available at: https://www.ncbi.nlm.nih.gov/books/NBK138654/. Accessed May 1, 2018.

35. Monleau M et al.; ANRS 12235 Study Group, 2014. Field evaluation of dried blood spots for routine HIV-1 viral load and drug resistance monitoring in patients receiving antiretroviral therapy in Africa and Asia. J Clin Microbiol 52: 578–586.

36. Monleau M, Montavon C, Laurent C, Segondy M, Montes B, Delaporte E, Boilot F, Peeters M, 2009. Evaluation of different RNA extraction methods and storage conditions of dried plasma or blood spots for human immunodeficiency virus type 1 RNA quantification and PCR amplification for drug resistance testing. J Clin Microbiol 47: 1107–1118.

37. Zida S et al., 2016. Estimation of HIV-1 DNA level interfering with reliability of HIV-1 RNA quantification performed on dried blood spots collected from successfully treated patients. J Clin Microbiol 54: 1641–1643.

38. Sawadogo S, Shiningavamwe A, Chang J, Maher AD, Zhang G, Yang C, Gaeb E, Kaura H, Ellenberger D, Lowrance DW, 2014. Limited utility of dried-blood- and plasma spot-based screening for antiretroviral treatment failure with Cobas Ampliprep/TaqMan HIV-1 version 2.0. J Clin Microbiol 52: 3878–3883.

39. Chang J et al., 2017. Performance characteristics of finger-stick dried blood spots (DBS) on the determination of human immunodeficiency virus (HIV) treatment failure in a pediatric population in Mozambique. PLoS One 12: e0181054.

40. Schmitz ME et al.; for VL–DBS Study Group, 2017. Field evaluation of dried blood spots for HIV-1 viral load monitoring in adults and children receiving antiretroviral treatment in Kenya: implications for scale-up in resource-limited settings. J Acquir Immune Defic Syndr 74: 399–406.

41. Baidjoe A et al., 2013. Combined DNA extraction and antibody elution from filter papers for the assessment of malaria transmission intensity in epidemiological studies. Malar J 12: 72.

42. Burnett JE, 2011. Dried blood spot sampling: practical considerations and recommendation for use with preclinical studies. Bioanalysis 3: 1099–1107.

43. Cobj Z et al., 2013. In-depth study of homogeneity in DBS using two different techniques: results from the EBF DBS-microsampling consortium. Bioanalysis 5: 2161–2169.

44. Caron A, Lelong C, Pascual M-H, Benning V, 2015. Miniaturized sampling techniques to benefit reduction in mice and refinement in nonhuman primates: applications to bioanalysis in toxicity studies with antibody-drug conjugates. J Am Assoc Lab Anim Sci 54: 145–152.

45. Spooner N, Lad R, Barfield M, 2009. Dried blood spots as a sample collection technique for the determination of pharmacokinetics in clinical studies: considerations for the validation of a quantitative bioanalytical method. Anal Chem 81: 1557–1563.

46. Chapman K, Chivers S, Gilddon D, Mitchell D, Robinson S, Sangster T, Sparrow S, Spooner N, Wilson A, 2014. Overcoming the barriers to the uptake of nonclinical microsampling in regulatory safety studies. Drug Discov Today 19: 528–532.

47. Nilsson LB, Ahooff M, Jonsson O, 2013. Capillary micro-sampling in the regulatory environment: validation and use of bioanalytical capillary microsampling methods. Bioanalysis 5: 731–738.

48. Amara AB, Else LJ, Carey D, Khoo S, Back DJ, Amin J, Emery S, Puls RL, 2017. Comparison of dried blood spots versus conventional plasma sample collection for the characterization of efavirenz pharmacokinetics in a large-scale global clinical trial—the ENCORE1 study. Ther Drug Monit 39: 654–658.

49. Kothare PA, Bateman KP, Dockendorf M, Stone J, Xu Y, Woolf E, Shipley LA, 2016. An integrated strategy for implementation of dried blood spots in clinical development programs. AAPS J 18: 519–527.

50. Antunes MV, Charão MF, Linden R, 2016. Dried blood spots analysis with mass spectrometry: potentials and pitfalls in therapeutic drug monitoring. Clin Biochem 49: 1035–1046.

51. Edelbroek PM, van der Heijden J, Stoel LML, 2009. Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther Drug Monit 31: 327–336.

52. Enderle Y, Foerster K, Burhenne J, 2016. Clinical feasibility of dried blood spots: analytics, validation, and applications. J Pharm Biochem Anal 130: 231–243.

53. Panchal T, Spooner N, Barfield M, 2017. Ensuring the collection of high-quality dried blood spot samples across multisite clinical studies. Bioanalysis 9: 209–213.

54. Li C-C et al., 2017. Population PK analyses of Ubrogepant (MK-1602), a CGRP receptor antagonist: enriching in-clinic plasma PK sampling with outpatient dried blood spot sampling. J Clin Pharmacol 58: 294–303.

55. Guerra Valero YC, Wallis SC, Lipman J, Stove C, Roberts JA, Parker SL, 2018. Clinical application of microsampling versus conventional sampling techniques in the quantitative bioanalysis of antibiotics: a systematic review. Bioanalysis 10: 407–423.

56. Wilhelm AJ, den Burger JCG, Swart EL, 2014. Therapeutic drug monitoring: by dried blood spot: progress to date and future directions. Clin Pharmacokinet 53: 961–973.

57. Muzembo BA, Mbendi NC, Nakayama SF, 2017. Systematic review with meta-analysis: performance of dried blood spots for hepatitis C antibodies detection. Public Health 153: 128–138.

58. Greenman J, Roberts T, Cohn J, Messac L, 2015. Dried blood spot in the genotyping, quantification and storage of HCV RNA: a systematic literature review. J Viral Hepat 22: 353–361.

59. Lange B et al., 2017. Diagnostic accuracy of detection and quantification of HBV-DNA and HCV-RNA using dried blood spot (DBS) samples—a systematic review and meta-analysis. BMC Infect Dis 17 (Suppl 1): 693.

60. Villar LM, de Oliveira JC, Cruz HM, Yoshida CFT, Lampo E, Lewis-Ximenez LL, 2011. Assessment of dried blood spot samples as a simple method for detection of hepatitis B virus markers. J Med Virol 83: 1522–1529.

61. Jardi R, Rodríguez-Frias F, Buti M, Schaper M, Valdes A, Martinez M, Esteban R, Guardia J, 2004. Usefulness of dried blood samples for quantification and molecular characterization of HBV-DNA. Hepatology 40: 133–139.

62. Bertagnolio S, Parkin NT, Jordan M, Brooks J, Garcia-Lerma JG, 2010. Dried blood spots for HIV-1 drug resistance and viral load testing: a review of current knowledge and WHO efforts for global HIV drug resistance surveillance. AIDS Rev 12: 195–208.

63. Hamers RL, Smit PW, Stevens W, Schuurman R, Rinke de Wit TF, 2009. Dried fluid spots for HIV type-1 viral load and resistance genotyping: a systematic review. Antivir Ther 14: 619–629.

64. Parkin NT, 2014. Measurement of HIV-1 viral load for drug resistance surveillance using dried blood spots: literature review and modeling of contribution of DNA and RNA. AIDS Rev 16: 160–171.

65. Adawaye C, Kamangu E, Moussa AM, Tchounbou B, Vaira D, Moutschen M, 2013. Use of dried blood spot to improve the diagnosis and management of HIV in resource-limited settings. World J AIDS 3: 251–256.

66. Johannesssen A, 2010. Dried blood spots in HIV monitoring: applications in resource-limited settings. Bioanalysis 2: 1893–1908.

67. Denniff P, Spooner N, 2010. The effect of hematocrit on assay bias when using DBS samples for the quantitative bioanalysis of drugs. Bioanalysis 2: 1385–1395.

68. De Kesel PM, Sadones N, Capiuia S, Lambert WE, Stove CP, 2013. Hemato-critical issues in quantitative analysis of dried blood spots: challenges and solutions. Bioanalysis 5: 2023–2041.

69. Chao TC, Trybala A, Starov V, Das DB, 2014. Influence of haematocrit level on the kinetics of blood spreading on thin porous medium during dried blood spot sampling. Colloids Surf A Physicochem Eng Asp 451: 38–47.
70. O’Mara M, Hudson-Curtis B, Olson K, Yueh Y, Dunn J, Spooner N, 2011. The effect of hematocrit and punch location on assay bias during quantitative bioanalysis of dried blood spot samples. Bioanalysis 3: 2335–2347.

71. Hall EM, Flores SR, De Jesús VR, 2015. Influence of hematocrit and total-spot volume on performance characteristics of dried blood spots for newborn screening. Int J Neonatal Screen 1: 69–78.

72. Lawson AJ, Bernstone L, Hall SK, 2016. Newborn screening blood spot analysis in the UK: influence of spot size, punch location and haematocrit. J Med Screen 23: 7–16.

73. Butler AM, Charoenvisnitwana W, Kranao P, Pankananjaro R, Thong-Ngao P, Polson RC, Snow G, Ehrenkranz J, 2017. Newborn thyroid screening: influence of pre-analytic variables on dried blood spot thyrotropin measurement. Thyroid 27: 1128–1134.

74. Fan L, Lee JA, 2012. Managing the effect of hematocrit on DBS analysis in a regulated environment. Bioanalysis 4: 345–347.

75. den Burger JCG, Wilhelm AJ, Chahbouni AC, Vos RM, Sinjewel A, Swart EL, 2015. Haematocrit corrected analysis of creatinine in dried blood spots through potassium measurement. Anal Bioanal Chem 407: 621–627.

76. Abu-Rabie P, Denniff P, Spooner N, Chowdhry BZ, Pullen FS, Jaffar R, 2015. Investigation of different approaches to incorporating internal standard in DBS, quantitative bioanalytical workflows and their effect on nullifying hematocrit-based assay bias. Anal Chem 87: 4996–5003.

77. Spooner N, Olutunji A, Webbley K, 2018. Investigation of the effect of blood hematocrit and lipid content on the blood volume deposited by a disposable dried blood spot collection device. J Pharm Biomed Anal 149: 419–424.

78. Polley SD, Bell D, Oliver J, Tully F, Perkins MD, Chiiodini PL, González JJ, 2015. The design and evaluation of a shaped filter collection device to sample and store defined volume dried blood spots from finger pricks. Malar J 14: 45.

79. Fang K, Bowen CL, Kellie JF, Karlenzy MA, Evans CA, 2018. Drug monitoring by volumetric absorbptive microsampling: method development considerations to mitigate hematocrit effects. Bioanalysis 10: 241–255.

80. Aylward LL, Hays SM, Smolders R, Koch HM, Cocker J, Jones K, Warren N, Levy L, Bevan R, 2014. Sources of variability in biomarker concentrations. J Toxicol Environ Health B Crit Rev 17: 45–61.

81. Tang K, 2017. Capillary blood for point-of-care testing. Crit Rev Clin Lab Sci 54: 294–308.

82. Kupke IR, Kather B, Zeugner S, 2011. Precision, accuracy, and reliability of hemoglobin analysis with use of capillary blood. Am J Clin Nutr 69: 1243–1248.

83. Kayiran SM, Ozbek N, Turan M, Gürakan B, 2003. Significant differences between capillary and venous complete blood counts in the neonatal period. Clin Lab Haematol 25: 9–16.

84. Zainabadi K, Adams M, Han ZY, Lwin HW, Han KT, Ouattara A, Thuma PE, Wright DW, 2017. Plasmodium falciparum HRP2 ELISA for analysis of dried blood spot samples in rural Zambia. Malar J 16: 350.

85. Jones S et al., 2012. Filter paper collection of Plasmodium falciparum mRNa for detecting low-density gametocytes. Malar J 11: 296.

86. Ren X, Paehler T, Zimmer M, Guo Z, Zane P, 2010. Effect of storage conditions on the cellular components of dried blood spots through potassium measurement. Bioanalysis 2: 1296–1300.

87. Zainabadi K, Adams M, Han ZY, Lwin HW, Han KT, Ouattara A, Thuma PE, Wright DW, 2017. Plasmodium falciparum HRP2 ELISA for analysis of dried blood spot samples in rural Zambia. Malar J 16: 350.
110. Kyle JE et al., 2017. Comparing identified and statistically significant lipids and polar metabolites in 15-year old serum and dried blood spot samples for longitudinal studies. *Rapid Commun Mass Spectrom* 31: 447–456.

111. Adam BW, Chafin DL, De Jesús VR, 2013. Stabilities of hemoglobin A and S in dried blood spots stored under controlled conditions. *Clin Biochem* 46: 1089–1092.

112. Lin Y-Q, Zhang Y, Li C, Li L, Zhang K, Li S, 2012. Evaluation of dry blood spot technique for quantification of an anti-CD20 monoclonal antibody drug in human blood samples. *J Pharmacol Toxicol Methods* 65: 44–48.

113. Meij LJ, Alexander JR, Adam BW, Hannon WH, 2001. Use of filter paper for the collection and analysis of human whole blood specimens. *J Nutr* 131: 1631S–1636S.

114. Adam BW, Hall EM, Sternberg M, Lim TH, Flores SR, O’Brien S, Simms D, Li LX, De Jesus VR, Hannon WH, 2011. The stability of markers in dried-blood spots for recommended newborn screening disorders in the United States. *Clin Biochem* 44: 1445–1450.

115. Han J, Higgins R, Lim MD, Lin K, Yang J, Borchers CH, 2017. Short-term stabilities of 21 amino acids in dried blood spots. *Clin Chem* 64: 400–402.

116. Golbahrar J, Altayaa DD, Carreon E, 2014. Short-term stability of amino acids and acylcarnitines in the dried blood spots used to screen newborns for metabolic disorders. *J Med Virol* 89: 264–266.

117. Grauholm J, Kho SK, Nickolov RZ, Poulsen JB, Baekvad-Hansen M, Hansen CS, Hougaard DM, Hollegaard MV, 2015. Gene expression profiling of archived dried blood spot samples from the Danish Neonatal Screening Biobank. *Mol Genet Metab* 116: 119–124.

118. Ho NT, Busik JV, Resau JH, Paneth N, Kho SK, 2016. Effect of storage time on gene expression data acquired from unfrozen archived newborn blood spots. *Mol Genet Metab* 119: 207–213.

119. Pupillo D, Simonato M, Cogo PE, Lapillonne A, Carnielli VP, 2016. Short-term stability of whole blood polysaturated fatty acid content on filter paper during storage at −28 °C. *Lipids* 51: 193–198.

120. Supriya M, De T, Christopher R, 2018. Effect of temperature on lysosomal enzyme activity during preparation and storage of dried blood spots. *J Clin Lab Anal* 32: e22220.

121. Elbitin CS, Olivova P, Marashio CA, Cooper SK, Cullen E, Keutzer JM, Zhang XC, 2011. The effect of preparation, storage and shipping of dried blood spots on the activity of five lysosomal enzymes. *Clin Chim Acta* 412: 1207–1212.

122. Adam BW, Orsini JJ, Martin M, Hall EM, Zobel SD, Caggana M, Hannon WH, 2011. The preparation and storage of dried-blood spot quality control materials for lysosomal storage disease screening tests. *Clin Biochem* 44: 704–710.

123. De Jesus VR, Zhang XK, Keutzer J, Bodamer OA, Müh l A, Orsini JJ, Caggana M, Vogt RF, Hannon WH, 2009. Development and evaluation of quality control dried blood spot materials in newborn screening for lysosomal storage disorders. *Clin Chem* 55: 158–164.

124. Flores SR, Hall EM, De Jesús VR, 2017. Glucose-6-phosphate dehydrogenase enzyme stability in filter paper dried blood spots. *Clin Biochem* 50: 878–881.

125. Jalln N, Azma RZ, Mohamed E, Ithnin A, Alaudhin H, Baya SN, Othman A, 2016. Evaluation of glucose-6-phosphate dehydrogenase stability in stored blood samples. *EXCLI J* 15: 155–162.

126. McAllister G, Shepherd S, Templeton K, Attkin C, Gunson R, 2015. Long-term stability of HBsAg, anti-HBc and anti-HCV in dried blood spot samples and eluates. *J Clin Virol* 71: 10–17.

127. Ndiaye O et al., 2017. Usefulness of dried blood spots (DBS) to perform hepatitis C virus genotyping in drug users in Senegal. *J Med Virol* 89: 484–488.

128. Parr JB et al., 2018. An efficient, large-scale survey of hepatitis C viremia in the Democratic Republic of the Congo using dried blood spots. *Clin Infect Dis* 66: 254–260.

129. Tejada-Strop A, Drobenic J, Mixon-Hayden T, Forbi JC, Ne T, Li M, Jei T, Terrault N, Kamili S, 2015. Disparate detection outcomes for anti-HCV IgG and HCV RNA in dried blood spots. *J Virol Methods* 212: 66–70.

130. Marques BL, Brandão CU, Silva EF, Marques VA, Villela-Nogueira CA, Do O K, de Paula MT, Lewis-Ximenez LL, Lampe E, Villar LM, 2012. Dried blood spot samples: optimization of commercial EIAs for hepatitis C antibody detection and stability under different storage conditions. *J Virol Methods* 184: 1600–1607.

131. David AL, Gilliland TC, Mital S, Pal S, Mitchell AC, Hontz RD, Wu S-JL, 2015. Evaluation of nucleic acid stabilization products for ambient temperature shipping and storage of viral RNA and antibody in a dried whole blood format. *Am J Trop Med Hyg* 93: 46–53.

132. Ruangturakit S, Rojanasuphott S, Srijuggravanvong A, Duangchainda N, Nutplaea S, Igarashia A, 1994. Storage stability of dengue IgM and IgG antibodies in whole blood and serum dried on filter paper strips detected by ELISA. *Southeast Asian J Trop Med Public Health* 25: 560–564.

133. Schwartz A, Baidjoe A, Rosenthal PJ, Dorsey G, Bousema T, Greenhouse B, 2015. The effect of storage and extraction methods on amplification of Plasmodium falciparum DNA from dried blood spots. *Am J Trop Med Hyg* 92: 922–925.

134. Strom GE, Mooy S, Fataki M, Langeland N, Blomberg B, 2014. PCR targeting *Plasmodium* mitochondrial genome of DNA extracted from dried blood on filter paper compared to whole blood. *Malar J* 13: 137.

135. Chaorattanakawee S, Nalangtachai H, Nacher M, Breckman A, Krudotsch S, Longo D, Loosweesuwan S, Patapaptokul J, 2009. Storage duration and polymerase chain reaction detection of *Plasmodium falciparum* from blood spots on filter paper. *Am J Trop Med Hyg* 69: 42–44.

136. Hwang J, Jaroenstic S, Leimanis ML, Russell B, McCreary R, Day N, Snounou G, Nosten F, Imwong M, 2012. Long-term storage limits PCR-based analyses of malaria parasites in archival dried blood spots. *Malar J* 11: 339.

137. Strom GE, Tellelevik MG, Hanevik K, Langeland N, Blomberg B, 2014. Comparison of four methods for extracting DNA from dried blood on filter paper for PCR targeting the mitochondrial *Plasmodium* genome. *Trans R Soc Trop Med Hyg* 108: 488–494.

138. Pritsch M, Wieser A, Soederstroem V, Poluda D, Esetu T, Hoelscher M, Schubert S, Shock J, Loescher T, Berens-Riha N, 2012. Stability of gametocyte-specific Pf25-mRNA in dried blood spots on filter paper subject to different storage conditions. *Malar J* 11: 138.

139. Corran PH et al., 2008. Dried blood spots as a source of anti-malarial antibodies for epidemiological studies. *Malar J* 7: 195.

140. García-Lerma JG, McNulty A, Jennings C, Huang D, Heneine W, Bremer JW, 2009. Rapid decline in the efficiency of HIV drug resistance genotyping from dried blood spots (DBS) and dried plasma spots (DPS) stored at 37 degrees C and high humidity. *J Antimicrob Chemother* 64: 33–36.

141. Youngpairoj AS, Masciotra S, Garrido C, Zahonero N, de Mendoza C, García-Lema JG, 2008. HIV-1 drug resistance genotyping from dried blood spots stored for 1 year at 4 degrees C. *J Antimicrob Chemother* 61: 1217–1220.

142. Attkin SC, Wallis CL, Stevens W, de Wit TR, Schuurman R, 2015. Stability of HIV-1 nucleic acids in dried blood spot samples for HIV-1 drug resistance genotyping. *PloS One* 10: e0131541.

143. Parry CM et al., 2014. Field study of dried blood spot specimens for HIV-1 drug resistance genotyping. *J Clin Microbiol* 52: 2868–2875.

144. Mitchell C et al.; Dried Blood Spot Working Group of the Infant Maternal Pediatric Adolescent AIDS Clinical Trials Network, 2008. Diminished human immunodeficiency virus type 1 DNA yield from dried blood spots after storage in a humid incubator at 37 degrees C compared to −20 degrees C. *J Clin Microbiol* 46: 2945–2949.

145. Monleau M, Butel C, Delaporte E, Boillot F, Peeters M, 2010. Effect of storage conditions of dried plasma and blood spots on HIV-1 RNA quantification and PCR amplification for drug resistance genotyping. *J Antimicrob Chemother* 65: 1562–1566.

146. Amellal B, Katlama C, Calvez V, 2007. Evaluation of the use of dried spots and of different storage conditions of plasma for HIV-1 RNA quantification. *HIV Med* 8: 396–400.

147. Wei X, Smith AJ, Forrest DW, Cardenas GA, Beck DW, LaLota M, Mestsch LR, Stonean C, Owen SM, Johnson JA, 2016. Incident infection and resistance mutation analysis of dried blood spots.
collected in a field study of HIV risk groups, 2007–2010. PLoS One 11: e0159266.

148. Begley CG, Ellis LM, 2012. Raise standards for preclinical cancer research. Nature 483: 531–533.

149. Luckwell J et al., 2013. Assessment of the within- and between-lot variability of Whatman™ FTA® (®) DMPK and 903® (®) DBS papers and their suitability for the quantitative bioanalysis of small molecules. Bioanalysis 5: 2613–2630.

150. Matheus S, de Laval F, Moua D, N’Guyen C, Martinez E, Rousset D, Briolant S, 2017. Zika virus persistence and higher viral loads in cutaneous capillaries than in venous blood. Emerg Infect Dis 23: 1910–1911.

151. Boghani S, Mei Z, Perry GS, Brittenham GM, Cogswell ME, 2017. Accuracy of capillary hemoglobin measurements for the detection of anemia among U.S. low-income toddlers and pregnant women. Nutrients 9: pii: E253.

152. Daae LN, Halvorsen S, Mathisen PM, Mikonska K, 1988. A comparison between haematological parameters in “capillary” and venous blood from healthy adults. Scand J Clin Lab Invest 48: 723–726.

153. Bancone G, Chu CS, Chowwiiwat N, Somksakchaicharoen R, Wilaisirisak P, Charunwatthana P, Bansil P, McGray S, Domingo GJ, Nosten FH, 2015. Suitability of capillary blood for quantitative assessment of G6PD activity and performances of G6PD point-of-care tests. Am J Trop Med Hyg 92: 818–824.

154. Kocisko DA, Walsh DS, Eamsila C, Edstein MD, 2000. Measurement of tafenoquine (WR 238605) in human plasma and venous and capillary blood by high-pressure liquid chromatography. Ther Drug Monit 22: 184–189.

155. Ashley EA, Stepniewska K, Lindegardh N, Annerberg A, Tarning J, McGeary R, Phaiphun L, Singhasivanon P, White NJ, Nosten F, 2010. Comparison of plasma, venous and capillary blood levels of piperacaine in patients with uncomplicated falciparum malaria. Eur J Clin Pharmacol 66: 705–712.

156. Dlawn PA, Daneau G, Coly AA, Ndiaye BP, Wade D, Camara M, Mboup S, Kestens L, Dieye TN, 2011. Multisite evaluation of a point-of-care instrument for CD4+ T-cell enumeration using venous and finger-prick blood: the PIMA CD4. J Acquir Immune Defic Syndr 58: e103–e111.

157. Steinmetzer K, Seidel T, Stallmach A, Ermantruet E, 2010. HIV load testing with small samples of whole blood. J Clin Microbiol 48: 2786–2792.

158. Bruns T, Steinmetzer K, Ermantruet E, Stallmach A, 2009. Hepatitis C virus RNA quantitation in venous and capillary small-volume whole-blood samples. J Clin Microbiol 47: 3231–3240.

159. Descloux E, La Fuentez C, Roca Y, De Lamballerie X, 2014. Clinical significance of intra-host variability of dengue-1 virus in venous and capillary blood. Clin Microbiol Infect 20: O167–O175.